US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 0.414
- +0.022+5.61%
Close Jan 3 16:00 ET
- 0.409
- -0.005-1.21%
Post 20:01 ET
20.55MMarket Cap-0.20P/E (TTM)
0.415High0.392Low569.32KVolume0.410Open0.392Pre Close228.07KTurnover1.37%Turnover RatioLossP/E (Static)49.63MShares4.17052wk High-0.24P/B17.18MFloat Cap0.30052wk Low--Dividend TTM41.50MShs Float71.500Historical High--Div YieldTTM5.77%Amplitude0.300Historical Low0.400Avg Price1Lot Size
BioXcel Therapeutics Stock Forum
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$Sportsman's Warehouse (SPWH.US)$ $Pharming Group (PHAR.US)$ $BioXcel Therapeutics (BTAI.US)$ $Gaxos.ai (GXAI.US)$ $Rigetti Computing (RGTI.US)$ $Quantum (QMCO.US)$ $MIND Technology (MIND.US)$ $Stitch Fix (SFIX.US)$ $Frequency Electronics (FEIM.US)$ $CleanCore Solutions (ZONE.US)$ $Silexion Therapeutics (SLXN.US)$ $SEALSQ Corp (LAES.US)$
📊⚡️📊
📊⚡️📊
5
1
$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share ("Comm...
$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia
Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer's dementia (AAD)
Estimated 140 ...
$BioXcel Therapeutics (BTAI.US)$ BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
$BioXcel Therapeutics (BTAI.US)$
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
$BioXcel Therapeutics (BTAI.US)$ …The Company expects unaudited revenue of approximately $1.1 million for the three months ended June 30, 2024, representing an increase of approximately 90% quarter over quarter and approximately 141% compared to the same period in 2023. Revenue growth was driven by an increase in contracting with psychiatric care clinics and behavioral health facilities using a small commercial team…
$BioXcel Therapeutics (BTAI.US)$ Sometimes when the chart hold decent? It pays to hold a Day trade overnight! But only when the chart says so and even then it can be a risk if bad news comes overnight!![]()
4
$BioXcel Therapeutics (BTAI.US)$ Note at 8:03 MooMoo has a high of 1.34! But as you see in pictures of chart and tic x tic the high was 1.47?
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...